Myriad Genetics Inc. Common Stock (MYGN)
Stock · NASDAQ · Health Care
$3.98as of 10/16/2026
Price chart
Active signals
MYGN Signal Track Record
How signals performed across all stocks →What MYGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -2.8% | 46% | September 10, 2026 |
| Bollinger Band Breakdown | 27 | -2.1% | 44% | July 27, 2026 |
| Bollinger Band Breakout | 17 | +6.8% | 71% | September 11, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -5.9% | 33% | July 22, 2026 |
| Any 20-session window (baseline) | -2.4% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MYGN
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and met…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 2,700
- Website
- myriad.com/
Fundamentals
- 1-day range
- $4.11$4.42
- Market cap
- $304.17M
- P/E (trailing)
- —
- P/E (forward)
- -7.39
- EPS (trailing)
- $-1.20
- Dividend yield
- —
- Beta
- 1.68
- Avg. volume
- 2.08M
How Myriad Genetics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Myriad Genetics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MYGNMyriad Genetics Inc. Common Stock$3.98▼ 8.51%Market cap $304.17MP/E —$2.74$8.59
- TKNOAlpha Teknova Inc. Common Stock$7.08▼ 6.84%Market cap $350.10MP/E —$1.91$9.48
- IMDXInsight Molecular Diagnostics Inc. Common Stock$3.01▼ 1.63%Market cap $154.99MP/E —$2.42$8.51
- ICCCImmuCell Corporation Common Stock$10.75▲ 1.80%Market cap $99.70MP/E 121.11$4.52$12.1
- QCLSQ/C Technologies Inc. Common Stock$0.538▼ 3.58%Market cap $21.99MP/E —$0.4201$8.17
- VNRXVolitionRX Limited Common Stock$0.18▼ 5.26%Market cap $9.23MP/E —$0.18$10.31
- TRIBTrinity Biotech plc American Depositary Shares$8.03▲ 1.26%Market cap $7.86MP/E —$5.01$52.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MYGN Myriad Genetics Inc. Common Stock | $304.17M | — | $3.98 | ▼ 8.51% | $2.74$8.59 |
| TKNO Alpha Teknova Inc. Common Stock | $350.10M | — | $7.08 | ▼ 6.84% | $1.91$9.48 |
| IMDX Insight Molecular Diagnostics Inc. Common Stock | $154.99M | — | $3.01 | ▼ 1.63% | $2.42$8.51 |
| ICCC ImmuCell Corporation Common Stock | $99.70M | 121.11 | $10.75 | ▲ 1.80% | $4.52$12.1 |
| QCLS Q/C Technologies Inc. Common Stock | $21.99M | — | $0.538 | ▼ 3.58% | $0.4201$8.17 |
| VNRX VolitionRX Limited Common Stock | $9.23M | — | $0.18 | ▼ 5.26% | $0.18$10.31 |
| TRIB Trinity Biotech plc American Depositary Shares | $7.86M | — | $8.03 | ▲ 1.26% | $5.01$52.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5benzinga · 10/13/2026
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyYahoo · 10/8/2026
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyYahoo · 10/8/2026
- SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score TechnologyBenzinga · 10/8/2026
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha · 10/7/2026
- Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split TargetsYahoo · 10/4/2026
- Why Is Myriad Genetics (MYGN) Stock Soaring TodayYahoo · 10/3/2026
- Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8Benzinga · 10/2/2026
- 1 Volatile Stock on Our Buy List and 2 We QuestionYahoo · 10/2/2026
Insider Activity
Insider Actions →- Wheeler Benjamin Richard · September 21, 2026 · Tax Withholding2.6K @ $4.01
- Sikri Vishal · September 16, 2026 · Grant257.7K
- Fox Jennifer Lynne · September 3, 2026 · Tax Withholding4.4K @ $3.23
- Wheeler Benjamin Richard · August 16, 2026 · Tax Withholding8.8K @ $3.03
- Donnelly Brian J · June 11, 2026 · Grant5.0K @ $3.94
- Raha Samraat S. · June 11, 2026 · Grant3.5K @ $3.94
- Kumar Rashmi · June 8, 2026 · Sale15.0K @ $4.46
- Mark Steven Davis · June 4, 2026 · Grant59.7K
- Kumar Rashmi · June 4, 2026 · Grant59.7K
- Lee Nisley Newcomer · June 4, 2026 · Grant59.7K
- Daniel Skovronsky · June 4, 2026 · Grant59.7K
- Reitan Colleen F · June 4, 2026 · Grant59.7K
- Phanstiel S. Louise · June 4, 2026 · Grant59.7K
- Dreismann Heinrich · June 4, 2026 · Grant59.7K
- Paul Bisaro · June 4, 2026 · Grant59.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 208.93M
- Total value held
- $477.28M
- Institutional holders
- 194
- Unknown125.00M
- Unknown8.89M
- Unknown6.67M
- Unknown5.41M
- Unknown4.50M
- Unknown4.42M
- Unknown3.92M
- Unknown3.17M
- Unknown2.37M
- Unknown2.32M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis
An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.